Zai Lab Limited (ZLAB)

16,25 -0,34 (-2,05%) Alla chiusura: 04:00PM EDT

Zai Lab Limited

Jinchuang Plaza
Building 1, Fourth Floor 4560 Jinke Road Pudong
Shanghai 201210
China
86 21 6163 2588
https://www.zailaboratory.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 2.175

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Ying Du Ph.D.	Founder, Chairperson & CEO	1,7M	N/D	1966
Mr. Joshua L. Smiley	President & COO	1,22M	N/D	1970
Dr. Rafael G. Amado M.D.	President and Head of Global Oncology Research & Development	1,6M	N/D	1964
Dr. Yajing Chen Ph.D.	Chief Financial Officer	624,56k	N/D	1968
Dr. Harald Reinhart M.D.	President and Head of Global Development for Neuroscience, Autoimmune & Infectious Diseases	951,03k	424,76k	1952
Dr. Peter Huang Ph.D.	Chief Scientific Officer	N/D	N/D	N/D
Ms. Christine Chiou	Senior VP & Head of Investor Relations	N/D	N/D	N/D
Mr. Frazor Titus Edmondson III, J.D.	Chief Legal Officer & Joint Corporate Secretary	829k	N/D	1966
Ms. Ann E. Beasley J.D.	Chief Compliance Officer	N/D	N/D	N/D
Dr. Ning Xu M.D.	Executive VP & Head of Clinical Operations	N/D	N/D	1965

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

Governance aziendale

L'ISS Governance QualityScore di Zai Lab Limited al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.